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Abstract: The purpose of this review is to describe research over the past 10 years on the role
of support services in promoting medication adherence in mental health consumers diagnosed
with schizophrenia. A literature search was conducted using the terms “medication adherence,”
“schizophrenia,” and “support services,” using Medline, PubMed, and CINAHL. Reference lists
from published studies were also reviewed to identify additional research studies. Twenty-two
articles focused on support-service intervention studies, and these were selected for review.
Available support-service interventions include adherence therapy, electronic reminders via
text messages and telephones, cognitive–behavioral and motivational strategies, and financial
incentives. Support-service intervention strategies need to be tailored to the specific needs of
mental health consumers with schizophrenia. More research is needed to investigate effective
support services to enhance long-term adherence and adherence to medications for medical
illnesses in this population.
Keywords: schizophrenia, medication adherence, support services, therapy, interventions

Introduction
Adherence to pharmacological treatment is essential for alleviation of psychotic
symptoms in schizophrenia. First-line antipsychotic medications are effective in
approximately 70%–80% of persons diagnosed with schizophrenia (PWS); however,
an estimated 50% of those who respond well to medications are nonadherent to their
treatment regimen.1 Wide variations have been observed in patterns of medication
adherence among PWS. Nonadherence can range from patients who refuse to take
medications due to lack of acceptance of the need for medication, to patients who
recognize the need for medication and are committed to treatment but are nonadherent due to forgetfulness or financial constraints.2 The consensus definition for adherence maintains that PWS can be considered adherent if they take more than 80% of
prescribed medications; partial adherence is defined as taking 50% of prescribed
medications.3 Velligan and colleagues also report a consensus among experts that
nonadherence can be defined as being off of medications for 1 week.3

Factors associated with medication nonadherence
Correspondence: Peggy El-Mallakh
315 College of Nursing Building,
Number 547, College of Nursing,
University of Kentucky, Lexington,
KY 40536, USA
Email peggy.el-mallakh@uky.edu

As the definitions of adherence suggest, the decision to take medications in PWS is
a complex phenomenon that involves multiple patient, environmental, provider, and
medication-related factors. Patient-related factors include some demographic characteristics, such as newly starting treatment, younger age at onset of illness, alcohol
dependence and other illicit substance use, homelessness, low levels of involvement
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in social activities, independent housing, and financial constraints with consequent inability to afford copayments for
prescriptions.4–9 Membership in a minority ethnic group also
contributes to poor medication adherence; in a large study
of 34,128 US veterans with schizophrenia, Valenstein et al10
reported that the relative risk ratio for consistently poor
adherence was 3.81 for African Americans compared to
whites and 3.54 for Hispanics compared to whites. Lack of
family support for adherence, or having no family, further
contributes to nonadherence. Glick et al11 and Moritz et al12
observed that a positive attitude toward positive symptoms,
particularly the perception of importance and power resulting
from psychotic symptoms, also contributes to nonadherence.
In addition, a study by Jόnsdόttir et al6 found that nonadherent PWS had significantly higher IQs, executive functioning, memory, and verbal learning/fluency compared to fully
adherent PWS.
Perceptions about illness and medications are very important factors that influence adherence. For example, adherence
is higher among PWS who have insight and an awareness
of the need to take medications to alleviate symptoms and
avoid hospitalization.7,13–15 In addition, favorable attitudes
toward mediations and the expectation that medications are
effective in reducing symptoms contribute to adherence.15,16
Intolerable side effects are a major reason for discontinuing
medications.12,15 For example, side effects associated with
typical antipsychotics, such as extrapyramidal symptoms,
sedation, and elevated prolactin levels, are particularly
problematic. Metabolic side effects of atypical antipsychotics, including weight gain, further contribute to lack of
adherence.17 However, some research suggests that recognition of the benefits of medications in alleviating troublesome
psychotic symptoms improves willingness to tolerate the
side-effect burden for the sake of mental wellness.18 Similarly, Liu-Seifert et al19 compared adherence among 1,103
people treated with olanzapine and 1,090 people treated with
other atypical antipsychotic medications (risperidone, quetiapine, ziprasidone, or aripiprazole). Findings suggested that
an improvement in the positive symptom rating subscale of
the Positive and Negative Syndrome Scale was the strongest
predictor of treatment adherence, regardless of the medication that was prescribed.
Much research supports the critical need for a strong
and positive therapeutic relationship in the promotion of
medication adherence.20,21 Misdrahi et al7 found that therapeutic alliance was significantly associated with medication
adherence (r=0.663) among 38 PWS. Similarly, Dassa et al16
found that nonadherence to medications increased with

1078

submit your manuscript | www.dovepress.com

Dovepress

Dovepress

a low level of therapeutic alliance (odds ratio =0.45, 95%
confidence interval =0.32–0.64) among 291 PWS. Research
also suggests that patients value support from prescribers
regarding medication, particularly when prescribers provided
accurate information about potential side effects of medication, expressed understanding of the patient perspective,
and listened to patients’ concerns about the medications. In
addition, Day et al20 reported that the experience of admission to the hospital is an important factor that influences
willingness to take medications; the perception of coercion,
lack of a voice in treatment decisions, and negative pressure
to enter the hospital are all associated with nonadherence to
psychiatric medications.

Adherence to medications for medical
illnesses
High rates of cardiometabolic problems among PWS have
prompted clinicians to focus on adherence to treatment for medical illnesses in this population. Research investigating adherence to medical care has yielded varying results. Pratt et al22
in a study of 72 participants with serious mental illnesses,
reported adherence rates of 57% for psychiatric medications
and 64% for medications for medical illnesses. Hansen et al 23
in a study of 87,015 PWS with comorbid medical illnesses,
found that adherence to medications for hypertension, hyperlipidemia, and diabetes was significantly greater among those
who were adherent to antipsychotic medications, with an
adjusted odds ratio of 6.9. In a study of 11,454 US veterans,
Kreyenbuhl et al24 found poor adherence to medications for
Type 2 diabetes mellitus (T2DM) in 43% of veterans with
schizophrenia and T2DM, compared to poor adherence rates
among 52% of veterans with T2DM and no mental illness.
Similarly, Nelson et al25 found that gaps in filled prescriptions
for antihyperlipidemic medications were 44 days for veterans diagnosed with schizophrenia and T2DM, compared to
62 days for veterans with T2DM and no mental illness.
Piette et al26 noted that in a study of 1,686 veterans diagnosed with schizophrenia and comorbid diabetes and hypertension, differential rates of adherence depended on the type
of medication prescribed to participants; findings suggest
that treatment with antihypertensive and diabetes medications was associated with an increased risk for low adherence compared to antipsychotic medications. Dolder et al27
found that rates of adherence to antihypertensive agents in
89 veterans with psychotic disorders were similar to rates
in 89 randomly selected, age-matched veterans without
psychotic disorders; however, blood pressure control was
significantly poorer over a 1-year period in the participants
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with psychotic disorders. In contrast, Dolder et al28 found
that among 76 middle-aged and older veterans with schizophrenia, 12-month adherence rates ranged from 52%–64%
for antipsychotic medications and medications to treat
hypertension, diabetes, and hyperlipidemia. Beebe et al29 in a
study that compared the effectiveness of a telephone intervention to improve medication adherence (n=15) to usual care
(n=14), found that average adherence rates to medications
for medical illnesses was 33% for the intervention group and
22% for the treatment-as-usual (TAU) group throughout the
duration of the study.

Consequences of nonadherence
Partial or complete lack of adherence to medications is associated with several negative outcomes in PWS.8,30 Medication
nonadherence is associated with an increased risk for relapse
of psychosis, persistent symptoms, and suicide attempts.8,31
Among PWS experiencing a first episode of psychosis,
symptom recurrence rates are an average of 77% within
1 year of stopping medications, and over 90% within 2 years
of stopping medications.30 Bodén et al32 found that nonadherence to medications during the first week after discharge from
an inpatient hospitalization was associated with a high risk
for rehospitalization within 1 month of discharge. Length of
hospital stay is also extended due to nonadherence.30 Finally,
Gilmer et al5 found that average hospital costs in nonadherent
inpatients were three times higher than costs for adherent
inpatients, although pharmacy costs were higher among
adherent compared to nonadherent inpatients.

Current strategies to improve adherence
Several support services are available to address specific
problems with adherence.33 For example, therapeutic support
services provide counseling, with the goal of identifying and
modifying cognitive and motivational barriers to adherence.
Cognitive-behavioral therapy (CBT) addresses inaccurate
beliefs and negative perceptions about medications and the
need for treatment.3 CBT is often used in conjunction with
motivational interviewing (MI), which seeks to resolve
ambivalence about taking medications and addresses perceptions about the importance of taking medications and
confidence in the ability to adhere to a medication regimen.34
Cognitive adaption training provides tailored environmental
cues and supports to compensate for cognitive impairments
that cause memory problems; these include alarms, pillboxes,
activity checklists, and organization of personal belongings.33
Adherence/compliance therapy is a multifaceted approach
that includes CBT, psychoeducation, and MI. 3 Support
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services can also address logistic barriers to adherence, such
as arranging transportation to pharmacies and obtaining
insurance benefits.3
This review summarizes research from the past 10 years
on interventions that examined the role of support services in
promoting adherence to psychiatric medications and medications for medical illnesses among PWS. A literature search
was conducted using the terms “medication adherence,”
“schizophrenia,” and “support services” and “interventions”
using Medline, PubMed, and CINAHL. Reference lists from
published studies were also reviewed to identify additional
research studies. A total of 22 articles were located using
these search terms and are included in this review.

Results
Findings from this literature review are displayed in
Tables 1–4. Of the 22 studies reviewed, eleven significantly
improved adherence to medications in the study samples, and
five did not result in significant improvements.

Support service interventions
Family and/or clinician support/education
Seven intervention studies examined the effectiveness of
family and/or clinician support and education (Table 1).35–41
Two family studies showed promising findings. Farooq et al37
implemented an intervention to train family members to be
key care supervisors of medication adherence (coupled with
free medications). Findings indicated that medication adherence was significantly increased in the intervention group.37
Kopelowicz et al39 found that culturally adapted multifamily
groups tailored to Spanish-speaking Mexican Americans,
who had three individual and family psychotherapy sessions,
a 1-day family workshop, and 24 family group sessions that
focused on attitudes, beliefs, planned behaviors, and subjective norms, had increased adherence compared to multifamily
groups only or TAU.
Interventions involving clinician support and education
yielded varying results. Sajatovic et al41 examined the effectiveness of a psychosocial/psychoeducational customized
adherence enhancement program for homeless people taking
long-acting antipsychotic injections (LAIs), which focused
on medication routines, communicating with clinicians, and
managing adherence in the presence of substance abuse. The
customized adherence enhancement program was associated
with good adherence to LAIs in 76% of participants. Oral
medication adherence improved to only 10% missed medication doses postintervention compared to 46% missed doses
prestudy. However, only four out of 30 continued taking
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1080
Monthly –
3 months
preintervention
to 6 months
postintervention
n=30
No control
group
MEMS
PANSS
DAI

AT – weekly
sessions for
8 weeks,
20–60 minutes
Focus: problem
solving,
medication
timeline,
ambivalence,
medication
beliefs/concerns,
using medications
in the future

Baseline
Postintervention

AT =12
TAU =14

ATSAT
LUNSERS
PANSS
PETiT

Intervention
description

Data collection
time points

Sample

Measures

Quasiexperimental
Compliance
therapy
4–6 sessions,
30–60 minutes
each
Focus: illness
history,
medication
beliefs/
understanding,
treatment
ambivalence,
stigma

RCT

Design type

Byerly et al36

Anderson et al35

Citation

Table 1 Family and/or clinician educational support
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PANSS
GAF
Adherence
to Medication
Scale

STOPS =55
TAU =55

Baseline,
3 months,
6 months,
12 months

STOPS – family
member as key
care supervisor
One session
to train key
care supervisor
Free
medications for
all participants
in STOPS
group and for
those in the
TAU group
who could
not afford
medications

RCT

Farooq et al37

MOS SF-36
SAI-E
MAQ
BPRS-E

AT =204
HE =205

AT – weekly
sessions
for 8 weeks
Focus:
problem
solving,
medication
timeline,
ambivalence,
medication
beliefs/
concerns,
using
medications
in the future
Health
education –
weekly
sessions for
8 weeks
Baseline and
52 weeks

RCT

Gray et al38

MFG-Ad =64
MFG =53
TAU =57
Treatment
Compliance
Interview

Culturally adapted
multifamily group
Tailored to Spanishspeaking MexicanAmericans (MFGAd) compared
to MFG-S and TAU
3 individual and
family sessions
One-day family
workshop
MFG-Ad: 24 family
group
sessions, focus:
attitudes,
beliefs, planned
behaviors
MFG-S: no focus on
attitudes, beliefs,
planned behaviors
Baseline, 4 months,
8 months, 12 months,
18 months,
24 months

3-armed RCT

Kopelowicz et al39

Self/caregiver
adherence report
Pharmacy refill
records
PANSS
QWBS
CDS
BAS
AIMS
DAI
ITAS
14-Q

AAI =22
TAU =18

Baseline, 4 weeks,
and 4 months

AAI – 9 sessions:
Face to face
daily ×3
Face to face
weekly ×3
Telephone
monthly ×3
Education, skills
training, alliance
building
Focus on
medication
management,
communication,
building
relationships
with health care
providers

RCT

Mittal et al40

Primary =
medication
adherence and
housing status
via self-reports:
TRQ
MRS
ATMSQ
DAI
Psychiatric
symptoms:
BPRS, PANSS, CGI
Functioning: SOFAS

Treatment =
baseline, 13, and 25
weeks follow-up;
Posttreatment
follow-up =9
and 12 months
n=30

Prospective,
noncontrolled trial
CAE, a
psychosocial/
psychoeducational
program about
medication
use plus haloperidol
decanoate-LAI =
CAE-L
administered over
6 months

Sajatovic et al41

El-Mallakh and Findlay
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No significant
improvements
in medication
adherence
or psychiatric
symptoms

Adherence
significantly
increased
1 month after
intervention,
declined by 1.4%
per month for
remaining
months
No change in
symptoms,
insight,
attitudes
to taking
medications

STOPS:
significant
reduction
in PANSS
scores,
positive/general
symptoms,
significant
improvement
in GAF
Significantly
higher
adherence
in the STOPS
group
compared
to TAU at
3 months,
6 months,
and 12 months
(67% vs 45%
at 1 year
follow-up,
P0.02)

No
significant
difference in
medication
adherence
and quality
of life
between AT
and HE
groups

MFG-Ad had
increased adherence
compared to MFG-S
and TAU
Longer time to first
hospitalization
Less likely to be
hospitalized

65% of AAI group
adherent after
4 months
55.6% TAU group
adherent
No significant
difference

CAE-L associated
with good
adherence to LAI
at 6 months =76%,
Overall oral
medication
adherence:
46% missed
prior to study
versus 10%
at 6 months
(P=0.03)
Only 4 continued
to take LAI
6 months
poststudy
Significant
improvements
in psychiatric
symptoms
(P0.001)
and functioning
(P0.001)

Abbreviations: 14-Q, 14-Point Questionnaire; AAI, antipsychotic adherence intervention; AIMS, Abnormal Involuntary Movement Scale; AT, adherence therapy; ATMSQ, Attitude Towards Mood Stabilizer Questionnaire; ATSAT,
Adherence Therapy Patient Satisfaction Questionnaire; BAS, Barnes Akathisia Scale; BPRS-E, Brief Psychiatric Rating Scale-Expanded; CAE, customized adherence enhancement program; CAE-L, customized adherence enhancement
plus long-acting injectable antipsychotic; CDS, Calgary Depression Scale; CGI, Clinical Global Impressions Scale; DAI, Drug Attitude Inventory; GAF, Global Assessment of Functioning; HE, health education; ITAS, Insight and Treatment
Attitude Scale; L or LAI, long-acting injection; LUNSERS, Liverpool University Neuroleptic Side Effect Rating Scale; MAQ, Medication Adherence Questionnaire; MEMS, Medication Event Monitoring Scale; MFG, multifamily group; MFG-Ad,
Multifamily Group-Adherence; MFG-S, Multifamily Group – Standard; MOS SF-36, Medical Outcomes Survey 36-item short form questionnaire; MRS, Morisky Rating Scale; PANSS, Positive and Negative Syndrome Scale; PETiT, Personal
Evaluation of Transitions in Treatment; QWBS, Quality of Well-Being Scale; RCT, randomized controlled trial; SAI-E, Schedule for the Assessment of Insight – Expanded Version; SOFAS, Social and Occupational Functioning Assessment
Scale; STOPS, supervised treatment in outpatients for schizophrenia; TAU, treatment as usual; TRQ, Tablet Routine Questionnaire.
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3 visits: baseline, 6 weeks,
and 8 weeks to measure
impact of DoPill’s®
(electronic pill dispenser)
impact on medication
adherence and psychiatric
symptoms

RCT 1-year prospective,
parallel-group, double-blind
study
Text message sent via
computer program:
ITAREPS 1 time/week
Active group prodromal
psychotic symptoms via
weekly ALERT emails
PIRE = triggered clinician
to increase antipsychotic
medication dose
Active group = used
ITAREPS and EWSQ-10P/
EWSQ-10FM + usual
treatment
Control group = usual
treatment
TIPS
Weekly telephone
calls for 3 months
Focus: problem
solving, coping
strategies, reminders
to take medications
Intervention
description

3 sets of 4 text messages
sent via mobile phone,
6 days per week for
12 weeks – CBT format
Focus: medication
adherence, socialization,
AH

Intervention group = daily
reminders for 3 months
via text message (SMS)
to take their medication
Control group = no
text reminders to take
medications

Quasi-experimental
waiting list controlled trial;
random assignment
6 weekly psychoeducation
group sessions with
5–7 patients
Weeks 1–2 = baseline
goals set (A1)
3 weeks = reminder texts
about adherence + usual
care = (B)
Last 3 weeks during
intervention = daily goals
achieved
3 weeks postintervention
= number
of daily goals
remeasured =(A2)
RCT open-label,
multicenter trial
RCT
Design type

Granholm et al42
Beebe et al29
Citation

Table 2 Electronic devices

A variety of electronics-based strategies were studied, including text messages, phone reminders, pill counters, electronic
pill dispensers, and a computerized program symptom alert
system (Table 2).29,42–46 Pijnenborg et al44 used text messages
in an intervention to examine the effectiveness of six weekly
group sessions focusing on coping with cognitive impairment associated with schizophrenia. The study also involved
instructions on how to send/receive text messages, including
a total of 7 weeks of receiving text messages as a reminder
to adhere to medications and other self-chosen treatment
goals. Adherence to medications in the intervention group
was 57% at baseline and 65% during the intervention, but
fell to 48% at follow-up when text prompts were no longer
being received. Granholm et al42 found that sending three
sets of four text messages about medication adherence,
socialization, and auditory hallucinations to people with
schizophrenia significantly improved medication adherence
for those living independently. Similarly, Montes et al43 found
that after sending daily short-message-service reminders or
texts for 3 months as a prompt to take medications, there was
a significantly reduced score on the Medication Adherence
Questionnaire (a four-item self-report of reasons for medication adherence failure, with a low score indicating better
adherence) in the intervention group at 3 months, and at
6 months adherence was maintained.
Beebe et al29 found that study participants who received
weekly telephone call reminders to take their medications

Montes et al43

Technology-based services

Quasi-experimental;
pilot study

Pijnenborg et al44

Španiel et al45

Stip et al46

LAI 6 months poststudy. In contrast, Byerly et al36 found
that adherence did not increase after four to six sessions
of compliance therapy that focused on illness history, and
medication beliefs, understanding, ambivalence, and stigma
of treatment. Anderson et al35 found no significant improvements in medication adherence following eight weekly
sessions of adherence therapy that included problem solving, exploration of ambivalence toward medication beliefs,
concerns, and using medications in the future. Similarly,
Gray et al38 found that there was no significant difference
in adherence between adherence therapy that included eight
weekly sessions about problem solving, medication timeline,
ambivalence, beliefs, and concerns about using them in the
future versus eight weekly health education sessions. Mittal
et al40 found that there was no significant difference between
antipsychotic adherence therapy versus TAU following nine
weekly sessions of daily, then weekly, face-to-face and
telephone education, alliance building, and skills training in
veterans aged 40 years and older.

RCT

El-Mallakh and Findlay
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n=55

TIPS =15
TAU =14

Pill counts

TIPS: 80% adherence
to psychiatric
medications;
33% adherence
to nonpsychiatric
medications
TAU: 60.1% adherence
to psychiatric
medications; 22%
adherence to
nonpsychiatric
medications
Significantly higher
adherence in TIPS
group vs TAU group

Sample

Measures

Findings

Neuropsychiatric Disease and Treatment 2015:11
MAQ
DAI
SUMD
EQ-5D
CGI-SCH
CGI-SI-DC
Significantly reduced
MAQ score with SMS
reminders vs controls
at 3 months (25% versus
17.5%) at 6 months,
maintained
MAQ score change from
baseline

SMS =100 patients
Controls =154 patients

Baseline, 3 months,
and 6-months

Overall % of goalachievement =47%
across patients, (SD
=27.9%) and increased
with text prompting =62%
(SD =20.1%, returned to
baseline levels without
prompts =40% (SD =31.7%);
Medication adherence = 57%
at baseline (A1), 65% at
intervention phase (B),
and 48% at follow-up (A2)

PANSS
SFS
SCMTS

Intervention group:
A1 + B + A2:
A1 = baseline phase,
B = intervention phase,
A2 = follow-up phase
Controls: A1 + A0 + B +
A2 (A0 = extra baseline
condition to control for
passing time)
n=62

No significant difference
in medication adherence
between groups

CGI-S and CGI-I
Hayward MCRS
GAF
PIRE detected by ITAREPS

Intervention =75
Controls =71

Baseline, 6 months, and
12 months (end of study)

Experimental group =26
Control group =21
47 total completed study
BARS
PANSS
DoPill® electronic/digital
report (frequency)
Antipsychotic Adherence
Ratio
46% non-adherent;
Baseline adherent patients
had significantly  adherence
vs non-adherent patients over
6-weeks via BARS measures; ie,
Mean AAR 67% after 6-weeks;
Proportion of patients
with 70% and 90%
AAR =46% and 54%

Baseline, 6 weeks,
and 8 weeks

Abbreviations: AAR, antipsychotic adherence ratio; AH, auditory hallucinations; BARS, Brief Adherence Rating Scale; BDI-II, Beck Depression Inventory-Second Edition; CBT, cognitive–behavioral therapy; CGI-I, Clinical Global
Impression Scale-Improvement; CGI-S, Clinical Global Impression Scale-Severity; CGI-SCH, Clinical Global Impression Scale-Schizophrenia; CGI-SI-DC, Clinical Global Impression-Severity of Illness and Degree of Change; CL, confidence
limit; DAI, Drug Attitude Inventory; EQ-5D, EuroQol; EWSQ-10FM, 10-item Early Warning Signs Questionnaire (Family Member); EWSQ-10P, 10-item Early Warning Signs Questionnaire (Patient); GAF, Global Assessment of
Functioning; ILSS, Independent Living Skills Survey; ITAREPS, Information Technology-Aided Program of Relapse Prevention in Schizophrenia; MAQ, Medication Adherence Questionnaire; MCRS, Medication Compliance Rating Scale;
PANSS, Positive and Negative Syndrome Scale; PIRE, pharmacological intervention requiring event; RCT, randomized controlled trial; SCMTS, Short Client Motivation for Therapy Scale; SD, standard deviation; SFS, Social Functioning
Scale; SMS, short message service; SUMD, Scale to Assess Unawareness of Mental Disorder; TAU, treatment as usual; TIPS, telephone intervention problem-solving.

Significant improvement
in medication adherence
for those living
independently; improved
social functioning; reduced
severity of AH

PANSS
BDI-II
ILSS

Baseline and 12 weeks

Baseline and monthly
for 3 months

Data collection
time points
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No significant differences
in medication adherence
between MI and HE;
reduced hospitalizations
for female patients in the
MI group

Findings

AT group: significant improvement
in PANSS scores, positive
symptoms, attitudes toward
medications, satisfaction
with medications
compared to TAU

AT =14
TAU =14
PANSS
GAF
DAI-30
SWAM
LUNSERS

Enhanced/RN counseling =173
Standard =176
PANSS
BARS
Schizophrenia Outcomes Module
Self-report/medical record review
for adherence

Veterans with enhanced guideline/RN
counseling significantly more likely
to be adherent at 6-month follow-up
Adherence at 6 months significantly
associated with adherence at baseline,
female sex, and negative baseline
akathisia

Baseline and 9 weeks

RCT
AT – 8 weekly sessions
Focus: medication problem solving,
ambivalence, beliefs, concerns
about taking medications, using
medications in the future

Maneesakorn et al49

Veterans Affairs practice
guideline implementation
RN counseling/problem solving
Clinical interview – baseline
and every visit
At least every 6 weeks for 6 months –
adherence barriers and strategies
Baseline and 6 months

Hudson et al48

TAT =54
TAU =55
SES
MAQ
DAI
CRS
PANSS
EQ-5D
Birchwood Insight Scale
TAT = significantly improved service
engagement and medication adherence
compared to TAU
TAT effect less at 6-month follow-up
but remained significant for medication adherence
No improvement in symptoms or quality of life

Baseline and 6 months

RCT
Intervention group/TAT = MI,
medication optimization, behavioral training
Control group = TAU

Staring et al50

Abbreviations: AT, adherence therapy; BARS, Brief Adherence Rating Scale; CRS, Compliance Rating Scale; DAI, Drug Attitude Inventory; DAI-30, Hogan Drug Attitude Inventory; EQ-5D, EuroQol; GAF, Global Assessment of
Functioning; HE, health education; LCS, Life Chart Schedule; LUNSERS, Liverpool University Neuroleptic Side Effect Rating Scale; MAQ, Medication Adherence Questionnaire; MI, motivational interviewing; PANSS, Positive and Negative
Syndrome Scale; RCT, randomized controlled trial; RN, registered nurse; SES, Service Engagement Scale; SWAM, Satisfaction with Antipsychotic Medication Scale; TAT, treatment adherence therapy; TAU, treatment as usual.

Measures

Baseline, 26 weeks,
6 months
MI =55
HE =59
PANSS
MAQ
LCS
DAI

Motivational interviewing
versus health education
5–8 sessions over 26 weeks

Barkhof et al47

Data collection
time points
Sample

Design type
Intervention
description

Citation
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Baseline to 12-month endpoint

Intervention =78, control =63

IT =2 years of assertive
outreach community treatment,
family psychoeducation, social
skills training/CBT

Baseline, 12 months, 24 months

IT =30
Control =20

Medication Adherence
(self, family and clinician reports)
Camberwell Family Interview
BPRS

No significant differences
in medication adherence
between IT and ST
Men more non-adherent
than women

Intervention
description

Data collection
time points

Sample

Measures

Neuropsychiatric Disease and Treatment 2015:11

Findings

Primary:
MPR
Secondary:
PANSS
QWBS
CSQ
MPRs = Meds-Help group
had significantly  MPRs at
6 months (Meds-Help MPR 0.91,
UC MPR 0.64) and 12 months
Meds-Help MPR 0.82, UC 0.62
(P0.0001)

12 months prior to enrollment
(baseline), 0–6 months,
and 6–12 months after
enrollment
Meds-Help =58
TAU =60

RCT with block-randomization
of patients (experimental
without double-blind)
Intervention: Meds-Help = unit-dose
medication packaging medication
education

Valenstein et al53

Medication adherence –
Pharm-CAT =90%
Med e-Monitor =91%
TAU =73%
Both Pharm-CAT and Med
e-Monitor significantly higher
than TAU

Pharm-CAT =46
Med e-Monitor =46
TAU =45
Medication adherence
SCID
BPRS
SOFAS
Service use

Baseline, 3 months, 6 months,
9 months

Pharm-CAT – tailored
environmental supports
and weekly home visits
Med e-Monitor – prompts
from an electronic device
in the patient’s home;
telephone contacts
TAU

3-armed RCT

Velligan et al54

Medication adherence significantly
higher in Full-CAT and Pharm-CAT
groups compared to TAU; remained
significantly higher after home visits
stopped

Full-CAT =34
Pharm-CAT =32
TAU =29
SCID
Pill counts
BPRS
SOFAS
Relapse Score

Full-CAT – tailored environmental
supports for independent living
skills, social/role performance,
medication adherence
Pharm-CAT – tailored
environmental supports
for medication and appointment
adherence only
TAU
Baseline, 3 months, 6 months,
9 months, 12 months, 15 months

3-armed RCT

Velligan et al33

Abbreviations: BPRS, Brief Psychiatric Rating Scale; CGI, Clinical Global Impressions Scale; CBT, cognitive–behavioral therapy; CSQ, Client Satisfaction Questionnaire; Full-CAT, full cognitive adaptation training; IT, integrated treatment;
LAI, long-acting injectable; MPR, medication possession ratio; PANSS, Positive and Negative Syndrome Scale; Pharm-CAT, cognitive adaptation training with medication education; QWBS, Quality of Well-Being Scale; RCT, randomized
controlled trial; SCID, Structured Clinical Interview for Diagnosis; SOFAS, Social and Occupational Functioning Assessment Scale; ST, standard treatment; TAU, treatment as usual; UC, usual care.

Modest financial incentives
improve adherence to LAI
12-month trial adherence:
intervention group =85%,
controls =71%
Secondary outcome adherence
of 95%: intervention group
=28% controls =5%

Medication adherence
CGI
DIALOG scale
Satisfaction with medication

RCT with cluster
randomization controlled
trial of treatment teams
Patients on intervention
teams who adhered 75%
of the time
4 months prior to screening
received financial incentive
of $22/clinic visit to receive
prescribed long-acting
antipsychotic injection

RCT

Design type

Priebe et al52

Morken et al51

Citation
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for psychiatric and medical conditions over 3 months had
significantly higher adherence compared to TAU controls.
Those in the intervention group were 80% adherent to psychiatric medications and 33% adherent to medications for
medical conditions.
Stip et al46 found that after 8 weeks of using an electronic
pill counter to assess medication adherence, 46% were nonadherent. The mean antipsychotic adherence ratio was 67%
after 6 weeks. Participants who were adherent at baseline
had significantly greater adherence versus those who were
nonadherent at baseline. Španiel et al45 found that after 1 year
of computer prompts to clinicians to increase antipsychotic
medication doses when participants reported psychotic symptoms (via an electronic message), there was no significant
difference in medication adherence in the intervention group
compared to controls.

Motivational interviewing interventions
MI was used in conjunction treatment adherence therapy
(TAT) and problem solving approaches (Table 3).47–50
Barkhof et al47 found that there were no significant differences in medication adherence after 26-week and 6-month
interventions of MI versus health education. Staring et al50
examined the effectiveness of 6 months of TAT, which
includes MI, medication optimization, and behavioral training, and found that TAT significantly improved medication
adherence. Findings also indicated that, despite a decrease
in effectiveness at the 6-month follow-up, adherence in the
intervention group remained significantly higher than in the
TAU group.
Hudson et al48 found that clinical interviews with a
registered nurse who asked people to identify barriers to
adherence and tailored strategies to overcome them via
problem solving at each clinic visit (minimum of every 6
weeks) for 6 months significantly increased adherence at
the 6-month follow-up. Adherence at 6 months was significantly associated with baseline adherence, female sex, and
no akathisia at baseline. Maneesakorn et al49 examined the
effectiveness of eight weekly sessions of adherence therapy
which focused on medication problem-solving, beliefs/
attitudes/ambivalence toward taking medications, and taking medications in the future. Findings indicated that the
participants in the adherence-therapy group showed significant improvements in positive symptoms, attitudes toward
medications, and satisfaction with medications. In this study,
medication adherence was not used as a primary outcome
measure; the authors noted that the outcomes of symptom
reduction and medication attitudes and satisfaction, rather
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than adherence, are indicators of the potential health gain
due to the intervention.49

Other support service interventions
A variety of other support interventions were examined
(Table 4); 33,51–54 these included integrated treatment,51
financial incentives,52 a pharmacy-based intervention,53 and
environmental supports.33,54 Morken et al51 found that a multifaceted program that implemented CBT along with assertive
outreach community treatment, family psychoeducation, and
social skills training, did not significantly improve medication adherence compared to TAU. Priebe et al52 found that
modest financial incentives, in the amount of $22 per clinic
visit, to receive an LAI during a 12-month trial increased
adherence from 75% at baseline to 85%, compared to 71%
among controls. Greater than 95% adherence was seen in
28% of the intervention group, compared to 5% in the control group. Valenstein et al found that, compared to controls,
patients using a pharmacy-based intervention that included
unit-dose prescriptions of medications for psychiatric and
medical conditions, medication education in packaging,
and refill reminders mailed 2 weeks in advance for 6 and
12 months had significantly increased medication possession
ratios (MPR, a measure that includes self-reports of adherence combined with pill counts and serum labs indicating
presence of medication).53
Environmental supports involved the use of home visits
and adaptation of participants’ home environment to incorporate cues as reminders to adhere to treatment. Velligan
et al54 found that home visits with full cognitive adaptation
training, a tailored environmental support system aimed at
improving independent living skills, and cognitive adaptation
training with medication education, a tailored environmental
support system for medication and appointment adherence,
significantly improved medication adherence in both groups
compared to the TAU group, and this difference remained
significant after home visits stopped.

Discussion
Findings suggest that the utility of available support services to enhance medication adherence depend on a variety
of factors, such as the PWS’s attitudes toward treatment,
perceptions of the need to take medications, and specific
environmental and cognitive characteristics. Technological
supports, such as mobile phone text message reminders, can
be beneficial to PWS who are committed to medication adherence and are occasionally nonadherent due to forgetfulness.
Similarly, interventions that focus on environmental cues to
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remind PWS to take their medications can be very helpful
in patients with memory problems.54 In contrast, findings
from this review suggest that therapeutic support services
are more appropriate to PWS who are ambivalent toward
taking medications and or deny the need to take medications. The most effective support service interventions are
tailored to the specific needs of PWS, use a problem-solving
approach to identify barriers to taking medications, and
address ambivalence that PWS have toward committing to
a life-long medication regimen.
Results of this literature review should be regarded with
caution due to some limitations in the study designs. Adherence
to psychiatric medications may depend on the participants’
age, financial constraints/affordability of medications, 9
adverse effects, severity of psychiatric symptoms, duration
of illness, side effects, and therapeutic response. Younger
age is a noteworthy predictor of nonadherence.4 However,
in the studies reviewed here, only two focused on younger
participants. One included family members as caregivers,39 in
which the mean age of participants was 24.6±8.3 years, and
one included participants with recent onset of symptoms;31
the mean age of participants in this study was 25.1±4.5 years.
In the remaining studies, the mean ages of participants ranged
from approximately 30–50 years, which limits generalizability to other age groups. Problems with medication adherence
due to financial constraints and affordability of medications
were not addressed in these studies, which is a noteworthy
gap that warrants further research.
Medication side effects are known contributors to poor
medication adherence among PWS.17 However, only three
studies in this review included a measure of side effects as
an outcome variable. Maneesakorn et al49 found reduced
scores on the Liverpool University Neuroleptic Side Effect
Rating Scale in the TAU group at a 9-week follow-up; the
authors attribute this to the higher number of participants
who were prescribed atypical antipsychotics in the TAU
group. Hudson et al48 found greater adherence associated with
negative baseline akathisia score. Finally, Sajatovic et al41
reported that in an adherence study that included LAIs, 40%
reported akathisia, but no significant changes were seen in
body mass index or total cholesterol. Findings from this
review suggest that further research is warranted to examine the degree to which adverse or side effects of the more
frequently used atypical antipsychotics influence medication
adherence, particularly related to the emergence of obesity
and cardiovascular/metabolic problems.
Severity of psychotic symptoms and level of cognitive
functioning can also influence medication adherence. In the

Neuropsychiatric Disease and Treatment 2015:11

Support services to improve medication adherence in schizophrenia

studies included in this review, all but four assessed symptom
severity at the outset of the studies. Rating measures included
the Positive and Negative Syndrome Scale, the Clinical
Global Impressions Scale, and the Brief Psychiatric Rating
Scale. Across all studies that measured symptoms, baseline
symptom severity scores ranged from very mildly to moderately ill. It is likely that PWS who experience very severe
symptoms are excluded from medication adherence research
because very severe symptoms prevent them from providing
informed consent for participation. Consequently, research
on medication adherence has limited generalizability toward
PWS with severe psychotic symptoms, and unfortunately
PWS who refuse or are unable to participate are most in need
of support services to improve adherence. In addition, participants’ treatment response was minimal in many of the studies,
as evidenced by nonsignificant changes in symptom severity
scores at the conclusion of the studies.33,35,36,42,43,45,53
Several authors also reported that PWS who refused to
participate in the studies had considerable deficits in cognitive functioning. Limitations on eligibility based on cognitive
functioning tended to limit the sample sizes, which ranged
from 25–409; the majority of studies had less than 100 participants. Several authors pointed out that eligibility based
on cognitive functioning and symptoms resulted in selection
bias, which increased the likelihood that participants had
higher levels of functioning.49
Very little longitudinal research has been conducted on
medication adherence over the lifetime trajectory of illness
among PWS; the maximum duration of time included in an
adherence study was 4 years.53 Patterns of adherence may be
unstable over time; Valenstein et al10 investigated patterns of
medication adherence, measured by MPR over a 4 year period
among 34,128 veterans with schizophrenia, and the findings
suggested that over 60% of veterans had adherence problems
at some point during the 4 year period. Findings also indicated that over a 4 year period, about 18% had consistently
poor adherence, defined as MPRs 0.8 in all 4 years; 43%
had inconsistent adherence, defined as MPRs 0.8 in some
years in the observation period, and 39% had consistently
good adherence, defined as MPRs 0.8 in all 4 years.
Very few reviewed studies focused on the effectiveness
of support services in improving adherence to medications
in the treatment of medical illnesses. Furthermore, it is
important to note that in the study conducted by Beebe et al29
the telephone intervention problem-solving intervention
improved adherence to psychiatric medications but not to
medications for medical illnesses. Problems with adherence
to medications for medical illnesses are by no means unique
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to PWS. Rates of medication nonadherence are about 50% in
the general population,55 which is essentially identical to rates
of nonadherence to psychiatric medications among PWS.1
Low adherence to medications in the general population
has been attributed to poor health literacy, intolerable side
effects, and unaffordable copayments.55 In addition, people
in the United States who are diagnosed with multiple chronic
medical illnesses often receive fragmented care from several
different providers, which results in complex medical regimens consisting of multiple medications.55
PWS who have complex comorbid medical illnesses
likely experience barriers similar to those found in the general population, particularly related to fragmented care.26
A supportive therapeutic alliance has been shown to promote
medication adherence in PWS, yet Piette et al26 have observed
that fragmented and poorly coordinated medical care from
multiple providers in different treatment settings is a considerable barrier to the development of a trusting relationship
between patients and provider. In addition, PWS have an
even greater risk for nonadherence compared to the general
population due to problems with motivation and cognitive
impairments that interfere with memory, attention, problemsolving, and health-related decision making.56
Adherence to medications that treat psychiatric and
medical illnesses is essential for PWS to achieve recovery
goals and optimize overall wellness, yet ongoing research
strongly suggests that physical health status and overall
wellness in this population are far from ideal. PWS suffer
from higher-than-average rates of comorbid chronic medical
illnesses and experience worse outcomes due to these illnesses compared to the general population, including higher
rates of emergency hospital admissions, longer length of
hospitalization for medical problems, and shorter length of
survival.57–59 Much attention has been focused on the recent
report that the life expectancy of PWS being served in the
US state mental health system is 25 years shorter than that
of the general population.60 These appalling morbidity and
mortality statistics illustrate health disparities that are increasingly untenable to patients, clinicians, policy makers, and
family members.61–63 A comprehensive initiative to reduce
health disparities, integrate physical and mental health care,
and improve mental and physical health status would need
to address multiple barriers to effective health care among
PWS, their providers, and health care delivery systems; the
development of more-effective support services to improve
adherence to medications for psychiatric and medical illnesses is foundational in this effort.64
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Implications for practice
As this review illustrates, several strategies are available to
prescribers to address medication adherence issues among
PWS. The essential first step is the establishment of a trusting
therapeutic relationship with the patient.7,16,20,21 In the event that
inpatient hospitalization is needed, PWS should be included in
treatment decisions as much as possible.20 Prior to implementation of support services, it is recommended that prescribers
work with the patient to conduct a root-cause analysis of reasons for nonadherence; implementation would target specific
support strategies to address them. It is recommended that
prescribers address adherence to psychiatric medications as a
priority and then address adherence to medications for medical illnesses as a secondary goal, since PWS have reported
that stable psychiatric symptoms are an essential precursor to
effective management of medical illnesses.56,65
Prescribers can also use cognitive strategies to link medication adherence to the patient’s treatment goals, such as
staying out of the hospital, living independently, maintaining
normal glycemic control, or returning to work or school, as
recommended in the Medication Treatment, Evaluation and
Management evidence-based practice.66 Finally, prescribers can promote optimal medication adherence by regularly
including PWS in decisions about medications and assessing
patient knowledge and attitudes about medications throughout the provision of support services.66
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